Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs
Executive Summary
Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets